



Patent
Attorney's Docket No. 029395-017

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE **RECEIVED**

In re Patent Application of)

Joyce TAYLOR-PAPADIMITRIOU et al.)

Application No.: 09/658,621)

Filed: September 8, 2000)

For: MUC-1 DERIVED PEPTIDES)

Group Art Unit: 1644

Examiner: Amy M. Decloux

Confirmation No.: 3359

AUG 07 2002

TECH CENTER 1600/2900

#14/c
Jm
8/8/02

RESPONSE

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Notice to Comply mailed July 2, 2002 (Paper No. 12), please
amend the above-identified application as follows.

IN THE SPECIFICATION:

Please replace the paragraph bridging pages 30-31, as follows:

Figure 11 shows that MUC1 derived HLA-A*0201 binding peptides induce peptide specific cytotoxic CTL responses. A2K^b mice were immunised twice with 100µg of MUC1 peptide in IFA and 140µg of Th peptide on day -28 and -14. On day 0 single cell splenocyte suspensions were restimulated *in vitro* for one week with peptide loaded syngeneic LPS-elicited lymphoblasts and tested for cytotoxicity of peptide loaded Jurkat-A*0201K^b. Groups of A2K^b mice were immunised with MUC1 peptides MUC1²⁶⁴⁻²⁷² (FLSFHISNL; SEQ ID NO:4), MUC1⁴⁶⁰⁻⁴⁶⁸ (SLSYTNPAV; SEQ ID NO:6), MUC1¹³⁻²¹ (LLLTVLTVV; SEQ ID